Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

GSK Announces Data From Five Phase III Studies Of Albiglutide - Quick Facts

RELATED NEWS
Trade GSK now with 

U.K.-based drug maker GlaxoSmithKline plc (GSK: Quote, GSK.L) announced data from five Phase III studies of albiglutide, an investigational once-weekly treatment for type 2 diabetes.

The company presented the data at the American Diabetes Association Meeting in Chicago from five long-term Phase III studies comparing albiglutide, an investigational glucagon-like peptide receptor agonist (GLP-1), to placebo and a range of active comparators.

The company said that the primary efficacy endpoint for these studies was the change from baseline in HbA1c compared to placebo and/or active comparators assessed after one or two years of treatment. Secondary endpoints included fasting plasma glucose or FPG and weight. These studies were specifically designed to assess durability of albiglutide effect on HbA1c and other continuous variables when used in various combination therapies, at different stages of the disease, and in various degrees of renal impairment.

According to the company Albiglutide achieved the primary efficacy endpoint in these five studies, although a hierarchical analysis of noninferiority to pioglitazone was not met in one study. The most commonly reported adverse reactions in these studies were gastrointestinal (GI) complaints, primarily nausea and diarrhoea, and injection site reactions.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. GLP-1 is a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating. In people with type 2 diabetes, GLP-1 secretion in response to a meal is reduced or absent. Albiglutide is currently undergoing regulatory review for the treatment of type two diabetes in the US and European Union.

Register
To receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
A number of major retailers will be open on Thanksgiving for early Black Friday shopping events. Kohl's department stores will kick off Black Friday sales two hours earlier this year, at 6 p.m. Thanksgiving Day, while Macy's, Bon-Ton and Best Buy will open at the same time. J.C. Penney and Sears... Twitter Inc. has replaced its head of product Daniel Graf just six months after luring him over from Google, according to multiple reports. Graf, previously known for his work leading Google Maps, will retain his vice president of product title and work on Twitter's geolocation features, the Wall... LinkedIn Corp., the world's largest online professional network, said Thursday after the markets closed that its third quarter loss widened slightly from last year, as higher costs and expenses more than offset a 45% increase in revenue. However, the company's quarterly earnings per share, excluding items, came in above analysts' expectations as did its quarterly revenue.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.